Development of a novel antibody-drug conjugate for treating t-cell lymphoma
Ended Project Grant Awarded Last action
- Award ID
- R41CA275639
- Recipient
-
Abcon Therapeutics, Inc. UEI YE2GVFPK6577
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,208,040
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Ohio, USA
Award details come from USAspending.gov.
Description
- Abstract
- T-cell lymphomas comprise up to 15% of all non-hodgkin's lymphoma. These complex clusters of blood cancers are very aggressive with poor (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $402,680 | |
| Amendment | $402,680 | |
| Original award | $402,680 |
Quick answers
Who received award R41CA275639?
R41CA275639 was awarded to Abcon Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2022.
How much is award R41CA275639 worth?
$1,208,040 has been obligated on R41CA275639.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award